Antareit

PreclinicalSmall molecule

VValenta Pharm JSC

Antareit is one of 27 small molecule programs targeting Oral. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OralRecruiting

OralPreclinical

Recruiting

Competition

Competitive Landscape

50 competitors in Oral

#DrugCompanyPhaseTrials

Vepesid

AAvyxa

Phase 2

1 2

Marinol

Jazz Pharmaceuticals

Phase 1

2 3

GTX-104

GGrace Therapeutics Inc.

Phase 3

1 4

SHR-3167

JJiangsu HengRui Medicine Co., Ltd.

Phase 2

1 5

Pitressin

AAultman Health Foundation

Preclinical

1 6

Nubain

AAultman Health Foundation

Preclinical

1 7

DRSP/EE

Vertex Pharmaceuticals

Phase 1

1 8

VX-407

Vertex Pharmaceuticals

Phase 1

1 9

AB-101

AArtiva Biotherapeutics, Inc.

Phase 1

1 10

Gas-X

PPortuguese Oncology Institute, Coimbra

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Oral1 trial

Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Riopan 800 mg Chewable Tablets in Healthy Volunteers

Recruiting·VValenta Pharm JSC·N/A·NCT06098742·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Antareit. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antareit compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antareit. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Valenta Pharm JSC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: VValenta Pharm JSC

Antareit

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Oral1 trial

References

Drug Info

Quick Facts

Related News